Regarding overall survival, the Kaplan–Meier survival curves were not significantly different for patients with HER2- and HER2low breast cancer, neither within the ER+ cohort nor in the ER- cohort (P = 0.295 and- P = 0.618 respectively; Fig. 3). This evidence concerns the gene ESR1 and breast cancer.